DK3500306T3 - Tripelkombination af inverse histamin-3-receptoragonister, acetylcholinesterasehæmmere og nmda-receptorantagonist - Google Patents
Tripelkombination af inverse histamin-3-receptoragonister, acetylcholinesterasehæmmere og nmda-receptorantagonist Download PDFInfo
- Publication number
- DK3500306T3 DK3500306T3 DK17764658.5T DK17764658T DK3500306T3 DK 3500306 T3 DK3500306 T3 DK 3500306T3 DK 17764658 T DK17764658 T DK 17764658T DK 3500306 T3 DK3500306 T3 DK 3500306T3
- Authority
- DK
- Denmark
- Prior art keywords
- histamin
- inverse
- triple combination
- acetylcholine esterase
- esterase inhibitors
- Prior art date
Links
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 title 1
- 238000003874 inverse correlation nuclear magnetic resonance spectroscopy Methods 0.000 title 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641028165 | 2016-08-18 | ||
| PCT/IB2017/054939 WO2018033848A1 (en) | 2016-08-18 | 2017-08-14 | Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3500306T3 true DK3500306T3 (da) | 2020-09-28 |
Family
ID=59829422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17764658.5T DK3500306T3 (da) | 2016-08-18 | 2017-08-14 | Tripelkombination af inverse histamin-3-receptoragonister, acetylcholinesterasehæmmere og nmda-receptorantagonist |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20190336509A1 (da) |
| EP (1) | EP3500306B1 (da) |
| JP (1) | JP6734469B2 (da) |
| KR (1) | KR102040639B1 (da) |
| CN (1) | CN109562180B (da) |
| AU (1) | AU2017311666B2 (da) |
| BR (1) | BR112019002637A2 (da) |
| CA (1) | CA3033050C (da) |
| CY (1) | CY1123522T1 (da) |
| DK (1) | DK3500306T3 (da) |
| EA (1) | EA036480B1 (da) |
| ES (1) | ES2818898T3 (da) |
| HR (1) | HRP20201511T1 (da) |
| HU (1) | HUE051474T2 (da) |
| IL (1) | IL264405B (da) |
| LT (1) | LT3500306T (da) |
| MA (1) | MA45988B1 (da) |
| MD (1) | MD3500306T2 (da) |
| MX (1) | MX377517B (da) |
| PL (1) | PL3500306T3 (da) |
| PT (1) | PT3500306T (da) |
| RS (1) | RS60832B1 (da) |
| SG (1) | SG11201900680PA (da) |
| SI (1) | SI3500306T1 (da) |
| SM (1) | SMT202000525T1 (da) |
| WO (1) | WO2018033848A1 (da) |
| ZA (1) | ZA201900436B (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3806859T3 (pl) * | 2018-05-31 | 2025-04-14 | Suven Life Sciences Limited | Sposób leczenia za pomocą odwrotnego agonisty receptora histaminowego h3 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013021496B1 (pt) * | 2011-02-23 | 2021-10-13 | Suven Life Sciences Limited | Composto, composição farmacêutica, uso da composição farmacêutica, processo para a preparação de um composto e uso do composto |
| FR2974729B1 (fr) * | 2011-05-02 | 2013-04-19 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
-
2017
- 2017-08-14 PL PL17764658T patent/PL3500306T3/pl unknown
- 2017-08-14 CN CN201780048908.1A patent/CN109562180B/zh not_active Expired - Fee Related
- 2017-08-14 LT LTEP17764658.5T patent/LT3500306T/lt unknown
- 2017-08-14 SI SI201730420T patent/SI3500306T1/sl unknown
- 2017-08-14 WO PCT/IB2017/054939 patent/WO2018033848A1/en not_active Ceased
- 2017-08-14 PT PT177646585T patent/PT3500306T/pt unknown
- 2017-08-14 DK DK17764658.5T patent/DK3500306T3/da active
- 2017-08-14 MA MA45988A patent/MA45988B1/fr unknown
- 2017-08-14 KR KR1020197007052A patent/KR102040639B1/ko not_active Expired - Fee Related
- 2017-08-14 HU HUE17764658A patent/HUE051474T2/hu unknown
- 2017-08-14 US US16/319,668 patent/US20190336509A1/en not_active Abandoned
- 2017-08-14 HR HRP20201511TT patent/HRP20201511T1/hr unknown
- 2017-08-14 MX MX2019001698A patent/MX377517B/es active IP Right Grant
- 2017-08-14 EP EP17764658.5A patent/EP3500306B1/en active Active
- 2017-08-14 BR BR112019002637A patent/BR112019002637A2/pt not_active IP Right Cessation
- 2017-08-14 JP JP2019506623A patent/JP6734469B2/ja not_active Expired - Fee Related
- 2017-08-14 SG SG11201900680PA patent/SG11201900680PA/en unknown
- 2017-08-14 AU AU2017311666A patent/AU2017311666B2/en not_active Ceased
- 2017-08-14 MD MDE20190713T patent/MD3500306T2/ro not_active IP Right Cessation
- 2017-08-14 CA CA3033050A patent/CA3033050C/en active Active
- 2017-08-14 ES ES17764658T patent/ES2818898T3/es active Active
- 2017-08-14 SM SM20200525T patent/SMT202000525T1/it unknown
- 2017-08-14 EA EA201990481A patent/EA036480B1/ru unknown
- 2017-08-14 RS RS20201135A patent/RS60832B1/sr unknown
-
2019
- 2019-01-22 ZA ZA2019/00436A patent/ZA201900436B/en unknown
- 2019-01-22 IL IL264405A patent/IL264405B/en active IP Right Grant
-
2020
- 2020-09-22 CY CY20201100891T patent/CY1123522T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1026I2 (fr) | Inhibiteurs de kras g12c | |
| DK3419625T3 (da) | Fremgangsmåder til anvendelse af fxr-agonister | |
| DK3419624T3 (da) | Fremgangsmåder til anvendelse af fxr-agonister | |
| DK3842442T3 (da) | Sammensætninger og fremgangsmåder til hæmning af arginaseaktivitet | |
| HUE057632T2 (hu) | KRAS G12C inhibitorok és eljárások alkalmazásukra | |
| DK3386534T3 (da) | Sammensætninger og fremgangsmåder til internalisering af enzymer | |
| DK3368541T3 (da) | Sammensætninger og metoder til inhibiering af arginaseaktivitet | |
| DK3350165T3 (da) | Farnesoid-X-receptoragonister og anvendelser deraf | |
| DK3442977T3 (da) | Inhibitorer af activinreceptorlignende kinase | |
| DK3247371T3 (da) | Fremgangsmåder til oprensning af cannabinoider, sammensætninger og kits dertil | |
| DK3303334T3 (da) | Tyrosinkinasehæmmere | |
| DK3482760T3 (da) | Kombination, der omfatter en ep4-antagonist og en immuncheckpoint-hæmmer | |
| DK3288946T3 (da) | 5-ht2c-receptoragonister og sammensætninger og anvendelsesfremgangsmåder | |
| EP3523315A4 (en) | INHIBITORS OF THE GLUCOCORTICOID RECEPTOR | |
| DK3380456T3 (da) | Kompleks af angiotensin receptor antagonist og neutral endopeptidase inhibitor | |
| DK3472338T3 (da) | Midler og fremgangsmåder til at modifikation af flere alleler | |
| EP3394078A4 (en) | INHIBITORS OF THE GLUCOCORTICIDE RECEPTOR | |
| DK3255046T3 (da) | Hydroxyethylsulfonat af cyclin-afhængig proteinkinasehæmmer, krystallinsk form deraf og fremgangsmåde til fremstilling deraf | |
| DK3280404T3 (da) | Fremgangsmåder til valg af phosphatase-selektive og ikke-selektive phosphatasehæmmere | |
| EP3394079A4 (en) | INHIBITORS OF GLUCOCORTICOIDREZEPTORS | |
| DK3119783T3 (da) | Inhibitorer af adapter associeret kinase 1, sammensætninger omfattende disse og fremgangsmåde til disses anvendelse | |
| DK3355699T3 (da) | Bicyklisk forbindelse og anvendelse deraf til inhibering af suv39h2 | |
| DK3551634T3 (da) | Substituerede pyrazoloazepin-8-oner og anvendelse deraf som phosphodiesterasehæmmere | |
| DK3551633T3 (da) | Substituerede pyrazoloazepin-4-oner og anvendelse deraf som phosphodiesterasehæmmere | |
| DK3439641T3 (da) | Sammensætninger, kits og fremgangsmåder til opretholselse af øjenlågshygiejne |